Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

301.76 +7.12 (+2.42%)
Streaming Delayed Price Updated: 1:43 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
The Best Biotech Stock to Invest $1,000 in Right Now
This stock may not be a slam dunk, but it's looking very promising. 
Via The Motley Fool
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
The company tested a GLP-1 drug in monkeys. But it might not actually be an obesity treatment. 
Via Investor's Business Daily
Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.
Eli Lilly just drizzled on Madrigal Pharmaceuticals' parade. 
Via The Motley Fool
Where Will Madrigal Pharmaceuticals Be in 3 Years?
The coast is clear for it to grow, for now. 
Via The Motley Fool
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Is Madrigal Pharmaceuticals Stock a Buy?
It's not the most prominent biotech, but it has an important claim to fame. 
Via The Motley Fool
2 Under-the-Radar Growth Stocks to Consider
Don't ignore these innovative companies. 
Via The Motley Fool
Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals
Success isn't guaranteed, but both companies could become big winners. 
Via The Motley Fool
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment.... 
Via Benzinga
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
Researchers published results Wednesday showing Lilly's weight-loss drug could work in a liver disease. 
Via Investor's Business Daily
DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug
Viking Therapeutics stock falls despite seemingly positive test results for a drug that treats a serious liver disease. 
Via Investor's Business Daily
1 No-Brainer Growth Stock to Buy Now
This liver-disease specialist might be significantly undervalued. 
Via The Motley Fool
Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock
This biotech just got clearance to dive into a deep ocean of a market. 
Via The Motley Fool
The Week Ahead: What's Next
The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle. 
Via Talk Markets
MDGL Stock Earnings: Madrigal Pharmaceuticals Misses EPS for Q1 2024
MDGL stock results show that Madrigal Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024
Analyst-backed stocks have a high correlation with future stock price growth. Here are seven stocks with a high number of recent upgrades. 
Via InvestorPlace
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics
These businesses should see good times ahead. 
Via The Motley Fool
The 3 Best Biotech Stocks to Buy in April 2024
Biotech is one of the hottest sectors on the market, creating big opportunities for some of the best biotech stocks to buy in April. 
Via InvestorPlace
2 Top Biotech Buyout Candidates
Investors who are adventurous, have a high-risk tolerance, and are home run hitters may opt for biotech stocks. Investors in this group may want to hone in on stocks that have the potential to be... 
Via Talk Markets
Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals
Both stocks are pretty risky, but one of them more so than the other. 
Via The Motley Fool
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?
Could it be just a matter of time before Madrigal Pharmaceuticals stock takes off? 
Via The Motley Fool
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?
The mid-cap biotech has succeeded where many others failed. 
Via The Motley Fool
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
Madrigal has one key advantage over its two huge potential future rivals. 
Via The Motley Fool
Exposures Product Safety
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. 
Via InvestorPlace
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.